Compare Enveric Biosciences Inc (ENVB) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Kroger Co — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Kroger Co trades at $58.11 (market cap $34.65B). The key difference: Kroger Co is far larger — about 6513.2× Enveric Biosciences Inc's market cap, and Kroger Co pays a 2.24% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | KR | |
|---|---|---|
Market Cap | $5.32M | $34.65B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $75.60 |
52-Week Low | $1.28 | $55.53 |
Enterprise Value | $408.82K | $54.75B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Kroger (KR) trades at $57.92, down 1.4% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows a high P/E of 55.29 but a low P/S of 0.28, with recent earnings beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company's $1.65 billion acquisition of Giant Eagle aims to expand its Midwest footprint, while cash flow trends remain volatile with a net cash flow of $2.08 billion in 2025.
The outlook is cautiously optimistic, supported by analyst consensus of $68.63 and a 47.72% buy rating, but risks include rising debt-to-asset ratios and competitive pressures. Near-term performance hinges on execution of the Giant Eagle integration and Q2 2026 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
